The future of gene therapy is precise vector targeting for in vivo delivery. Targeting specific cells streamlines complex and costly ex vivo workflows while improving on-target efficiency for in vivo applications. Our Cellective and G-Link reagents retarget VSV-G-based vectors to CD3 for enhanced transduction and in vivo delivery.
Cellective and G-Link CD3-targeted vectors efficiently transduce resting T cells, streamlining workflows and reducing reliance on costly activation reagents. Furthermore, T cells are activated during transduction, supporting sustained proliferation.
Efficient, highly specific in vivo delivery that integrates seamlessly into your standard lentiviral vector (LV) production workflows. Ready to go in vivo when you need it.
Cellective and G-Link both redirect VSV-G using a protein adapter, but the two technologies offer distinct workflows and functional profiles. Cellective involves a permanent covalent linkage and requires a specialized VSV-G, while G-Link uses a non-covalent interaction compatible with standard wild-type VSV-G.
Need to target a different receptor? Contact us if you have a specific target in mind.
